EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: Implications for targeted radiotherapy

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Shen, Li ^a   Shui, Yongjie ^a   Wang, Xiaojia ^b   Sheng, Liming ^a   Yang, Zhengyan ^b   Xue, Danfeng ^b   Wei, Qichun ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PELVIS LYMPHADENECTOMY; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; SCORING SYSTEM; UTERINE CERVIX CARCINOMA; BIOLOGICAL MODEL; BIOSYNTHESIS; CARCINOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE; RADIOTHERAPY; UTERINE CERVIX TUMOR;

ADULT; AGED; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; UTERINE CERVICAL NEOPLASMS;

EID: 50549101389     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-232     Document Type: Article

References (35)

1. Parkin DM Bray F Ferlay J Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 15761078
2. Long HJ 3rd Bundy BN Grendys EC Jr Benda JA McMeekin DS Sorosky J Miller DS Eaton LA Fiorica JV: Gynecologic Oncology Group Study Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005, 23:4626-4633. 10.1200/JCO.2005.10.021 15911865
3. Green JA Kirwan JM Tierney JF Symonds P Fresco L Collingwood M Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 2001, 358:781-786. 10.1016/S0140-6736(01)05965-7 11564482
4. Morris M Eifel PJ Lu J Grigsby PW Levenback C Stevens RE Rotman M Gershenson DM Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999, 340:1137-1143. 10.1056/NEJM199904153401501 10202164
5. Rose PG Bundy BN Watkins EB Thigpen JT Deppe G Maiman MA Clarke-Pearson DL Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999, 340:1144-1153. 10.1056/NEJM199904153401502 10202165
6. Eifel PJ Winter K Morris M Levenback C Grigsby PW Cooper J Rotman M Gershenson D Mutch DG; Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004, 22:872-880. 10.1200/JCO.2004.07.197 14990643
7. Classe JM Rauch P Rodier JF Morice P Stoeckle E Lasry S Houvenaeghel G: Groupe des Chirurgiens de Centre de Lutte Contre le Cancer Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervicalRcancer: Morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol 2006, 102:523-529. 10.1016/ j.ygyno.2006.01.022 16504274
8. Keys HM Bundy BN Stehman FB Muderspach LI Chafe WE Suggs CL 3rd Walker JL Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999, 340:1154-1161. 10.1056/NEJM199904153401503 10202166
9. Hirte HW Strychowsky JE Oliver T Fung-Kee-Fung M Elit L Oza AM: Chemotherapy for recurrent, metastatic, or persistent cervical cancer: A systematic review. Int J Gynecol Cancer 2007, 17:1194-1204. 10.1111/ j.1525-1438.2007.00900.x 17540006
10. Lenhard RE Jr Osteen RT Gansler T: Eds Clinical Oncology Atlanta, GA: American Cancer Society, Inc 2001
11. Duenas-Gonzalez A Cetina L Mariscal I de la Garza J: Modern management of locally advanced cervical carcinoma. Cancer Treat Rev 2003, 29:389-399. 10.1016/S0305-7372(03)00068-9 12972357
12. Carlsson J Forssell Aronsson E Hietala SO Stigbrand T Tennvall J: Tumour therapy with radionuclides: Assessment of progress and problems. Radiother Oncol 2003, 66:107-117. 10.1016/S0167-8140(02)00374-2 12648782
13. Goldberg RM: Cetuximab. Nat Rev Drug Discov Suppl 2005, S10:11. 10.1038/ nrd1728
14. Ciardiello F Caputo R Bianco R Damiano V Pomatico G De Placido S Bianco AR Tortora G: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053-2063. 10815932
15. Hightower M: Erlotinib (OSI-774, Tarceva), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2003, 4:336-338. 14599299
16. Bonner JA Harari PM Giralt J Azarnia N Shin DM Cohen RB Jones CU Sur R Raben D Jassem J Ove R Kies MS Baselga J Youssoufian H Amellal N Rowinsky EK Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/ NEJMoa053422 16467544
17. Souglakos J Kalykaki A Vamvakas L Androulakis N Kalbakis K Agelaki S Vardakis N Tzardi M Kotsakis AP Gioulbasanis J Tsetis D Sfakiotaki G Chatzidaki D Mavroudis D Georgoulias V Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 2007, 18:305-310. 10.1093/annonc/mdl392 17079693
18. Hanna N Lilenbaum R Ansari R Lynch T Govindan R Janne PA Bonomi P: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006, 24:5253-5258. 10.1200/JCO.2006.08.2263 17114658
19. Barnes DM Miles DW: Response of metastatic breast cancer to trastuzumab?. Lancet 2000, 355:160-161. 10.1016/S0140-6736(99)00430-4 10675110
20. Goncalves A Fabbro M Lhommé C Gladieff L Extra JM Floquet A Chaigneau L Carrasco AT Viens P: A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008, 108:42-46. 10.1016/j.ygyno.2007.07.057 17980406
21. Cho NH Kim YB Park TK Kim GE Park K Song KJ: P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol 2003, 91:346-353. 10.1016/S0090-8258(03)00504-3 14599865
22. Kristensen GB Holm R Abeler VM Trope CG: Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. Cancer 1996, 78:433-440. 10.1002/(SICI)1097-0142(19960801)78:3<433::AID- CNCR9>3.0.CO;2-K 8697388
23. Kersemaekers AM Fleuren GJ Kenter GG Broek Van den LJ Uljee SM Hermans J Vijver Van de MJ: Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999, 5:577-586. 10100709
24. Hale RJ Buckley CH Gullick WJ Fox H Williams J Wilcox FL: Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993, 46:149-153. 501147 8459036 10.1136/ jcp.46.2.149
25. Kim GE Kim YB Cho NH Chung HC Pyo HR Lee JD Park TK Koom WS Chun M Suh CO: Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clin Cancer Res 2004, 10:1366-1374. 10.1158/ 1078-0432.CCR-0497-03 14977838
26. Lee CM Lee RJ Hammond E Tsodikov A Dodson M Zempolich K Gaffney DK: Expression of HER2neu (c-erbB-2) and epidermal growth factor receptor in cervical cancer: Prognostic correlation with clinical characteristics, and comparison of manual and automated imaging analysis. Gynecol Oncol 2004, 93:209-214. 10.1016/j.ygyno.2004.01.006 15047238
27. Gaffney DK Haslam D Tsodikov A Hammond E Seaman J Holden J Lee RJ Zempolich K Dodson M: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:922-928. 10.1016/S0360-3016(03)00209-8 12829126
28. Lee JS Kim HS Jung JJ Lee MC Park CS: Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 2002, 85:469-475. 10.1006/gyno.2002.6648 12051876
29. Nevin J Laing D Kaye P McCulloch T Barnard R Silcocks P Blackett T Paterson M Sharp F Cruse P: The significance of Erb-b2 immunostaining in cervical cancer. Gynecol Oncol 1999, 73:354-358. 10.1006/gyno.1999.5396 10366459
30. Niibe Y Nakano T Ohno T Suzuki Y Oka K Tsujii H: Prognostic significance of c-erbB-2/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. Int J Gynecol Cancer 2003, 13:849-855. 10.1111/j.1525-1438.2003.13397.x 14675323
31. Chavez-Blanco A Perez-Sanchez V Gonzalez-Fierro A Vela-Chavez T Candelaria M Cetina L Vidal S Duenas-Gonzalez A; HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004, 4:59. 517717 15341668 10.1186/1471-2407-4-59
32. Kim JY Lim SJ Park K Lee CM Kim J: Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 2005, 97:337-341. 10.1016/j.ygyno.2004.09.012 15863127
33. Wei Q Sheng L Shui Y Hu Q Nordgren H Carlsson J: EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008, 15:1193-1201. 10.1245/s10434-007-9771-3 18172732
34. Shang J Shui Y Sheng L Wang K Hu Q Wei Q: Epidermal growth factor receptor and human epidermal growth factor receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy. Oncol Rep 2008, 19:435-440. 18202792
35. Bilous M Dowsett M Hanna W Isola J Lebeau A Moreno A Penault-Llorca F Rüschoff J Tomasic G Vijver van de M: Current perspectives on HER2 testing: A review of National Testing Guidelines. Mod Pathol 2003, 16:173-182. 10.1097/01.MP.0000052102.90815.82 12591971